KOL Insight Archives | Report Store

Non-Small Cell Lung Cancer KOL Interview

Biomedtracker interviewed a lung cancer specialist based in the US to determine his views on the non-small cell lung cancer treatment landscape, with a focus on PD-1 immunotherapies.

December 16, 2016

Find out more

HIV Pre-Exposure Prophylaxis (HIV PrEP) KOL Interview – US #1

$599.00

This interview with a US-based key opinion leader (KOL) provides insights into prescribing habits, key marketed brands, and late-phase pipeline therapies for HIV PrEP. Drug pricing and reimbursement, as well as unmet needs, are also discussed. Key pipeline assets highlighted include islatravir and cabotegravir.

August 10, 2021

Find out more

Treatment of VTE – US KOL Interview

$599.00

This interview with a US hematologist focuses on the changing dynamics with the introduction of novel/direct oral anticoagulants (NOAC, DOAC) in the treatment of venous thromboembolism (VTE) and prevention of recurrence.

November 2, 2015

Find out more

Datamonitor Healthcare Chronic Heart Failure KOL Interview – Germany

$599.00

A German KOL discusses current marketed therapies and SGLT-2 inhibitors for chronic heart failure, as well as key unmet needs in this therapeutic area.

February 4, 2019

Find out more

2015 Breast Cancer Pulse #2

$599.00

This 5-question pulse of 24 oncologists practicing in the United States focuses on the usage of HER2-targeted agents for the treatment of breast cancer.

May 26, 2015

Find out more

Datamonitor Healthcare Meningococcal and Pneumococcal Vaccines KOL Interview – US

$599.00

An interview with a US key opinion leader (KOL) on meningococcal and pneumococcal vaccination coverage rates, vaccination rate trends in main risk groups, key marketed vaccines, pipeline approaches, and addressing unmet needs.

November 9, 2018

Find out more

Ebola KOL Interview #3

$599.00

Ebola KOL Interview #3

December 2, 2014

Find out more

Chronic Lymphocytic Leukemia (CLL) KOL Interview – US

$599.00

A US-based key opinion leader (KOL) provides insights into prescribing habits, key marketed brands, and late-phase pipeline therapies for CLL. Key pipeline assets highlighted include the CAR-T therapy Breyanzi, reversible BTK inhibitors MK-1026 and pirtobrutinib, and the PI3K inhibitor TG-1303.

October 1, 2020

Find out more

Datamonitor Schizophrenia KOL Interview 2

$599.00

KOL believes that the available schizophrenia treatments that provide the most efficacy also have the highest side effects.

February 24, 2016

Find out more

Hemophilia KOL Interview – US, Southeast

$599.00

A US-based key opinion leader (KOL) provides insights into prescribing habits, key marketed drugs, and late-phase pipeline therapies for hemophilia, including alternative coagulation promoters and gene therapies. Unmet needs are also discussed. The main marketed products covered include Hemlibra, Advate, and BeneFIX, and key pipeline assets highlighted are valoctocogene roxaparvovec (valrox), fitusiran, and concizumab.

March 20, 2020

Find out more

Chronic Migraine Survey

$599.00

Datamonitor conducted a 5-question survey of 26 United States and 25 European (based in France, Germany, Italy, Spain and United Kingdom) neurologists involved in pain management to gauge current prescribing practices in prophylactic treatment of chronic migraine and potential future use of the calcitonin gene-related peptide (CGRP) receptor targeting monoclonal antibody (mAb) AMG 334 (AMGN) and CGRP targeting mAbs ALD403 (ALDR) and TEV-48125 (TEVA).

March 9, 2017

Find out more

2015-cll-pulse-2-drug-usage-and-reimbursement

2015 Chronic Lymphocytic Leukemia (CLL) Pulse

$599.00

We performed a 5-question survey of 40 hematology-oncology specialists in the US to gauge current prescribing practices and physician experience with reimbursement for ibrutinib and idelalisib for the treatment of patients with CLL.

January 27, 2015

Find out more

Melanoma KOL Interview – US #2

$599.00

This interview with a US-based key opinion leader (KOL) provides insights into prescribing habits, key marketed brands, and late-phase pipeline therapies for melanoma. Treatment strategies split by disease stage, as well as unmet needs, are also discussed. Key pipeline assets highlighted include lifileucel, seviprotimut-L, Lenvima, and TAVO.

February 25, 2022

Find out more

Major Depressive Disorder KOL Interview – UK

$599.00

A UK key opinion leader (KOL) provides insight into the critical unmet needs in the depression market, along with future trends. Key late-phase pipeline drugs for major depressive disorder and post-partum depression are covered, with particular focus on Johnson & Johnson’s esketamine.

December 19, 2018

Find out more

Zontivity Approval: Views on Efficacy/Bleeding and Projected Usage Survey

$599.00

Zontivity was approved (May 8, 2014) for use with clopidogrel/aspirin, its label was relatively benign, not reporting bleeding in the overall trial, which included stroke/TIA patients who had excessive bleeding with the drug, or in ACS trial, where there was also excessive bleeding.

May 13, 2014

Find out more

Post-Clinical Trials on Alzheimer’s Disease (CTAD) 2016 Survey

$599.00

Biomedtracker conducted a 5-question survey of 51 United States and 47 European (from France, Germany, Italy, Spain and United Kingdom) neurologists who currently treat patients in all stages of Alzheimer’s disease and who followed data presented at Clinical Trials on Alzheimer’s Disease (CTAD) 2016 to gauge their views on the pipeline anti-amyloid beta monoclonal antibodies solanezumab (LLY) and aducanumab (BIIB) and projected use of these potentially disease-modifying drugs if FDA-approved.

March 9, 2017

Find out more

2015 Jardiance EMPA-REG CVOT Pulse

$599.00

This 5-question survey of 30 primary care physicians and 29 endocrinologists in the United States evaluates the impact of the EMPA-REG cardiovascular outcomes trial (CVOT) of SGLT2 inhibitor Jardiance (Boehringer, LLY).

November 1, 2015

Find out more

Schizophrenia and Bipolar Disorder KOL Interview – US, East Coast

$599.00

This interview with a US-based key opinion leader (KOL) provides insights into prescribing habits, key marketed brands, long-acting injectables, late-phase pipeline therapies, and unmet needs for schizophrenia and bipolar disorder. Key pipeline assets highlighted include Lybalvi (ALKS 3831), MIN-101, Nuplazid, Caplyta, BXCL501, and six-monthly paliperidone depot injection.

April 28, 2021

Find out more

Alzheimer’s KOL Interview

$399.00

KOL is optimistic on amyloid-targeted therapy and believes IV therapy will be tolerated if approved.

October 21, 2015

Find out more

Biomedtracker Q3 2017 Outlook Report

$599.00

In this report, we cover catalysts from 21 drugs expected to occur in Q3 2017. For each drug, the likelihood of Phase/PDUFA review success and overall Likelihood of Approval (LOA) given their particular phase, drug class, and disease group are provided.

August 2, 2017

Find out more

Abuse-Deterrent Opioids Survey KOL Interview

$599.00

Biomedtracker performed a 5-question survey of 30 United States primary care physicians who currently treat patients with chronic pain and prescribe opioids to at least some of their patients with chronic pain to gauge current and future use of abuse-deterrent opioids to treat chronic pain.

March 9, 2017

Find out more

Multiple Sclerosis (MS) KOL Interview – UK, Southwest

$599.00

In this interview, a UK-based key opinion leader (KOL) discusses typical prescribing habits for disease-modifying therapies (DMTs) in MS. This includes first-generation DMTs and the newer, more potent entrants like Ocrevus, as well as late-stage pipeline DMTs.

March 2, 2020

Find out more

GLP-1 Pulse Survey

$599.00

This survey of US primary care physicians (n=10) and endocrinologists (n=10) was undertaken to evaluate the impact of GLP-1 agonists if they were to be introduced in the Diabetes market.

August 25, 2014

Find out more

Multiple Myeloma KOL Interview – UK

$599.00

This interview with a UK-based key opinion leader (KOL) provides insights into prescribing habits, key marketed brands, and late-phase pipeline therapies for multiple myeloma. Drug adverse events and UK market access issues are also discussed. Key therapies highlighted include Darzalex, Venclexta, Xpovio, Ygalo, Blenrep, and BCMA-targeted CAR-T therapies.

May 15, 2020

Find out more

Multiple Sclerosis (MS) KOL Interview – US, Midwest

$599.00

In this interview, a US-based key opinion leader (KOL) discusses typical prescribing habits for disease-modifying therapies (DMTs) in MS. This includes first-generation DMTs and the newer, more potent entrants like Ocrevus, as well as late-stage pipeline DMTs.

March 2, 2020

Find out more

Acute Myeloid Leukemia (AML) KOL Interview – US, South

$599.00

A US-based key opinion leader (KOL) provides insights into prescribing habits, key marketed brands, and late-phase pipeline therapies for acute myeloid leukemia (AML). Critical unmet needs are also discussed. Key pipeline assets highlighted include idasanutlin, oral azacitidine, and pevonedistat.

March 14, 2022

Find out more

Post-AAIC KOL Interview

$599.00

Crenezumab data was negative in a Phase II study in mild to moderate AD. The signal in not pre-specified isn’t convincing. These data likely will have ethical implications for the asymptomatic, genetic AD predisposition study in the Columbian trial.

August 6, 2014

Find out more

Datamonitor Healthcare Infectious Diseases Disease Analysis: Seasonal Influenza Vaccines

$599.00

The seasonal influenza vaccines market in the US, Japan, and five major European markets (France, Germany, Italy, Spain, and the UK) is expected to continue to expand over the next 10 years, largely due to the continued uptake of premium-priced vaccines in the elderly subgroup, including quadrivalent forms of Fluzone High-Dose (HD) and Fluad, as well as the launch of the first-in-class adjuvanted nanoparticle vaccine, NanoFlu.

October 30, 2020

Find out more

Rheumatoid Arthritis KOL Interview – California, US

$599.00

A US-based key opinion leader provides insights into prescribing habits, the most pressing unmet needs in the market, the role of biosimilars, key marketed brands, and late-phase pipeline therapies for rheumatoid arthritis, including upadacitinib and filgotinib.

July 31, 2019

Find out more

Datamonitor Healthcare Chronic Heart Failure KOL Interview – US, Southwest

$599.00

A US KOL provides insight into marketed and pipeline therapies for chronic heart failure, as well as key unmet needs in this therapeutic area. Key marketed drugs are highlighted, including Corlanor and Entresto. Significant late-phase pipeline drugs are also covered, with a focus on SGLT-2 inhibitors.

February 4, 2019

Find out more

Post-EASL KOL Insight Interview

$599.00

The European Association for the Study of the Liver (EASL) held the 2014 International Liver Meeting in
London from April 9-13. The main focus of this year’s meeting was the clinical use of currently approved and
soon-to-be approved, direct-acting antivirals for Hepatitis C.

May 6, 2014

Find out more

2015 PCSK9 Inhibitors Pulse

$599.00

Following the approval of the first PCSK9 Inhibitor, Praluent (SNY, REGN), this 5- question survey of 23 cardiologists evaluated attitudes towards the class, projected usage prior to their CVOTs depending on insurance prior authorization, preference of Praluent vs Repatha (AMGN), and how the oral CETP inhibitors would impact PCSK9 usage under different outcomes study scenarios.

August 19, 2015

Find out more

Schizophrenia and Bipolar Disorder Payer Interview – US, South

$599.00

This interview with a US-based key opinion leader (KOL) provides insights into pricing and reimbursement dynamics and issues concerning schizophrenia and bipolar disorder, with a focus on oral antipsychotics and long-acting injectables.

April 28, 2021

Find out more

Depression KOL Interview – US #1

$599.00

A US expert in the depression field dives into the treatment algorithm, critical unmet needs, and pipeline drugs such as SAGE-217 and AXS-05.

March 2, 2021

Find out more

Datamonitor Healthcare Major Depressive Disorder KOL Interview – US #2

$599.00

A US key opinion leader (KOL) discusses the approach to treating major depressive disorder as well as the most pressing unmet needs in the market, and provides insights into key late-phase pipeline drugs for major depressive disorder.

October 2, 2018

Find out more

Multiple Sclerosis (MS) KOL Interview – UK, London

$599.00

In this interview, a UK-based key opinion leader (KOL) discusses typical prescribing habits for disease-modifying therapies (DMTs) in MS. This includes first-generation DMTs and the newer, more potent entrants like Ocrevus, as well as late-stage pipeline DMTs.

March 2, 2020

Find out more

2018 ASH Pulse Survey

$599.00

This 9-question pulse survey of 102 hematologic oncologists practicing throughout the United States and Europe.

January 2, 2019

Find out more

Pneumococcal Vaccines KOL Interview

$599.00

Datamonitor interviewed three infectious diseases specialists to determine the physicians’ views on marketed and pipeline pneumococcal vaccines. Two physicians were based in Chicago, IL and one in the UK. The three interviews were combined into a single report.

August 27, 2016

Find out more

Ebola KOL Interview #1

$599.00

So the history in Africa has been very extensive since the 1970s and outbreaks in those countries havehappened sporadically over the last 40 years. Here in US, right, this is our first case of anyone being sick with Ebola, and there are a number of people who have actually come into the country.

November 2, 2014

Find out more

Ulcerative Colitis (UC) KOL Interview – UK

$599.00

A UK expert in the ulcerative colitis (UC) field dives into the treatment algorithm, critical unmet needs, and pipeline drugs, such as the Janus kinase inhibitors and sphingosine 1-phosphate (S1P) modulators.

March 1, 2021

Find out more

Acute Lymphocytic Leukemia KOL Interview

$599.00

[Newer treatments] are definitely being used in the relapse population, and that’s where they made their mark like most other investigational agents for other cancers. I think the issue is that the response rate with initial induction therapy is so high. Whether or not there is going to be a maintenance-type study strategy, that’s a question with some of these therapies that are relatively low toxicity, but when you have a complete remission rate of 90-95%, and ALL’s not the most common disease – it’s a pretty rare cancer actually – that it’s going to be difficult to do large studies for indications in the randomized setting.

February 9, 2016

Find out more

Respiratory Syncytial Virus (RSV) Prevention KOL Interview – US #2

$599.00

This interview with a US-based key opinion leader (KOL) provides insights into upcoming changes in treatment algorithms, trial data for late-phase pipeline prophylaxis therapies, competitive positioning, and vaccination coverage rates. Pricing and reimbursement, as well as unmet needs, are also discussed. Key pipeline assets highlighted include nirsevimab, RSVpreF, and GSK3844766A.

December 22, 2021

Find out more

Datamonitor Healthcare Non-Alcoholic Steatohepatitis (NASH) KOL Interview – US

$599.00

This interview with a US key opinion leader (KOL) provides insight into pipeline therapies for non-alcoholic steatohepatitis (NASH), as well as pricing strategies, diagnostic tools, and future treatment rates for the different fibrosis stages of NASH. Key pipeline assets highlighted include Ocaliva, elafibranor, cenicriviroc, and firsocostat.

May 20, 2019

Find out more

Post-CHDI Huntington’s Disease KOL Interview

$799.00

Indications: Huntington’s Disease, Alzheimer’s Disease Physician Information Specialty: Neurology Location: London, United Kingdom

March 16, 2015

Find out more

2016 Biomedtracker Post-EASL Hepatitis C Survey

$599.00

We performed a 9-question survey of 29 EU and 31 US hepatologists and gastroenterologists after the European Association of the Study of the Liver (EASL) International Liver Conference (ILC) from April, 2016 in Barcelona to gauge current and projected prescribing practices for hepatitis C virus (HCV) infection.

May 16, 2016

Find out more